Introduction
Pulsed field ablation (PFA) utilizes intermittent, high-intensity
electric field for short durations (micro- or nanoseconds) to achieve
cell death through irreversible electroporation.1,2,3Most unique to PFA is its tissue selectivity.4 That
is, different tissues have specific characteristic threshold field
strengths that induce necrosis.5 Preclinical and
clinical studies have found that cardiac myocytes in general exhibit a
lower threshold for irreversible electroporation as compared to phrenic
nerve (PN) or esophageal tissue.6,7,8,9 In this
preclinical study, we demonstrate the feasibility and safety of two
novel, 8-French, 16-electrode, single-shot, bipolar, spiral PFA/mapping
catheters (CRC EP, Inc, Tustin, CA).